Readers like you keep news free for everyone.

More than 5,000 readers have already pitched in to keep free access to The Journal.

For the price of one cup of coffee each week you can help keep paywalls away.

Support us today
Not now
Tuesday 5 December 2023 Dublin: 4°C
NIAID via Flickr

Potent drug brings us closer than ever to a HIV vaccine

The drug candidate has been shows to stop every strain of HIV.

SCIENTISTS IN FLORIDA have created a new drug candidate that is so potent and universally effective that it could work as part of an unconventional vaccine.

The research shows that the new drug candidate blocks every strain of HIV-1, HIV-2 and SIV (simian immunodeficiency virus) that has been isolated from humans or monkeys – including the hardest-to-stop variants.

It also protects against much-higher doses of virus than occur in most human transmission and does so for at least eight months after injection.

Scientists from more than a dozen research institutions were involved in the research conducted at the Jupiter, Florida campus of The Scripps Research Institute (TSRI).

“Our compound is the broadest and most potent entry inhibitor described so far,” said Michael Farzan, a TSRI professor who led the effort. “Unlike antibodies, which fail to neutralize a large fraction of HIV-1 strains, our protein has been effective against all strains tested, raising the possibility it could offer an effective HIV vaccine alternative.”

When HIV infects a cell, it targets an integral part of the body’s immune system, fusing with the cell and inserting its own genetic material.

It then transforms the host cell into a HIV manufacturing site. The new study builds in previous discoveries which show that a co-receptor called CCR5 contains unusual modifications in its HIV binding region and that proteins based on this region can be used to prevent infection altogether.

Farzan and his team developed a new drug candidate so that it binds to two sites on the surface of the virus simultaneously, preventing entry of HIV to the host cell.
The team also leveraged preexisting technology in designing a delivery vehicle—an engineered adeno-associated virus, a small, relatively innocuous virus that causes no disease.

Once injected into muscle tissue, like HIV itself, the vehicle turns those cells into “factories” that could produce enough of the new protective protein to last for years, perhaps decades, Farzan said.

He said when original work was done on CCR5, people thought it was interesting but no one saw the therapeutic potential.

“The potential is starting to be realised.”

Read: This smartphone gadget will tell you if you have an STD or not>

Read: A 5-year-old girl contracted HIV from a blood transfusion>

Your Voice
Readers Comments
    Submit a report
    Please help us understand how this comment violates our community guidelines.
    Thank you for the feedback
    Your feedback has been sent to our team for review.